It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purpose
This study aimed to construct and validate a novel nomogram for prediction of lymph node metastasis in HER2-positive breast cancer based on the optimal number of examined lymph nodes (ELNs) for accurate nodal staging.
Methods
We included 4,040 patients diagnosed with HER2-positive breast cancer from the SEER database, randomly allocating them into training and validation cohorts in a 7:3 ratio. The optimal number of ELNs was identified via piecewise linear regression. The association of ELNs count with nodal migration was evaluated through Logistic Regression (LR) analysis and Random Forest (RF). The nomogram was constructed, and its’ performance was evaluated by the receiver operating characteristic curves, calibration curve and Decision curve analysis curves.
Results
The optimal number of ELNs was 13. LR and RF identified the optimal number of ELNs, radiotherapy status, chemotherapy status, T stage, and grade as independent predictive variables for node metastasis, which were used in the nomogram’s construction. And the area under the curve values for the nomogram were 0.829 (95% confidence interval (CI): 0.813–0.845) and 0.833 (95% CI:0.808–0.858) in the training and test split respectively, surpassing those of the optimal number of ELNs (0.649, 95% CI: 0.631–0.667 and 0.676, 95% CI:0.648–0.704). Calibration plots exhibited low Brier scores (0.150 for training split, 0.145 for test split).
Conclusion
This study developed a novel nomogram that integrates the optimal number of ELNs with other independent risk factors, facilitating individualized prediction of lymph node metastasis in patients with HER2-positive breast cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer